Resultados de la búsqueda 41-50 of 1393 for ���������������������������op������r���:za33���

1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   ... (R/R DLBCL). Rochester, Minn. Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel ...

2. Mayo Clinic Urology Physician Update — April 2025

   Page 1.

3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...

4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   ... (R/R FL), who have completed at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy. Study of Tumor-treating Fields to Treat ...

5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   ... (R/R FL), who have completed at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy. Study of Tumor-treating Fields to Treat ...

6. Hematología - Ensayos clínicos - Mayo Clinic

   Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...

7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and ...

8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on ...

9. Mayo Clinic Cardiovascular Physician Update - April 2025

   Page 1.

10. Cirugía - Ensayos clínicos - Mayo Clinic

    Data will contribute to creating treatment algorithms for symptom management for upper digestive diseases and for post-operative complications and symptoms as ...